Organisation paid for research Program year 2025 Source: CMS Open Payments

Foundation for Vision Research

Neither a doctor nor a teaching hospital

Research payments

$1,401,951

273 payments

Through program year 2025, Foundation for Vision Research is reported as receiving $1,401,951 in research payments, across 273 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$275,266	77
2024	Research	$321,559	69
2023	Research	$437,711	50
2022	Research	$222,723	45
2020	Research	$59,569	13
2019	Research	$85,123	19

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $749,086 185 payments
Janssen Research & Development, LLC $271,568 60 payments
EyePoint Pharmaceuticals US, Inc. $242,969 6 payments
Neurotech Pharmaceuticals, Inc. $116,370 17 payments
Regeneron Pharmaceuticals, Inc. $8,779 2 payments
Alimera Sciences, Inc. $8,179 2 payments
Roche TCRC, Inc. $5,000 1 payment

Studies the money was for Research payments · program years 2019–2025

Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $264,891 52 payments
Port Delivery System of Ranibizumab Extension Study $260,326 59 payments
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular $233,062 47 payments
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $218,345 3 payments
Ntmt-03C $116,370 17 payments
Port Delivery System of Ranizibumab Extension Study $81,145 19 payments
Faricimab Dme Long Term Extension Rhone X $42,042 17 payments
Mad to Assess the Safety Tolerability and PK PD in Namd Patients $34,996 11 payments
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies $34,095 10 payments
Port Delivery System for Ranibizumab $32,801 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.